Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Critical Reviews in Toxicology|September 28, 2010
1,3-Butadiene: II. Genotoxicity profileRichard J Albertini, M Leigh Carson, Christopher R Kirman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 10, 2003
Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humansLisa M Sweeney, Michael L Gargas, Dale E Strother, et al.
Toxicology|May 26, 2009
Contribution of trichloroacetic acid to liver tumors observed in perchloroethylene (perc)-exposed miceLisa M Sweeney, Christopher R Kirman, Michael L Gargas, et al.
Journal of Toxicology and Environmental Health. Part A|January 11, 2003
A physiologically based pharmacokinetic model for acrylamide and its metabolite, glycidamide, in the ratChristopher R Kirman, Michael L Gargas, Randy Deskin, et al.
Toxicology Letters|April 4, 2008
Disposition of styrene-acrylonitrile (SAN) trimer in female rats: single dose intravenous and gavage studiesMichael L Gargas, Brad Collins, Timothy R Fennell, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|December 2, 2009
Development of a physiologically-based toxicokinetic model of acrylamide and glycidamide in rats and humansLisa M Sweeney, Christopher R Kirman, Michael L Gargas, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|December 2, 2009
Estimation of safe dietary intake levels of acrylamide for humansRobert G Tardiff, Michael L Gargas, Christopher R Kirman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 31, 2009
Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modelingTorka S Poet, Chris R Kirman, Michael Bader, et al.
Chemico-Biological Interactions|August 1, 2006
Cancer risk assessment for 1,3-butadiene: dose-response modeling from an epidemiological perspectiveRobert L Sielken, Ciriaco Valdez-Flores, Michael L Gargas, et al.
Regulatory Toxicology and Pharmacology : RTP|December 27, 2011
Assessing the non-cancer risk for RDX (hexahydro-1,3,5-trinitro-1,3,5-triazine) using physiologically based pharmacokinetic (PBPK) modelingLisa M Sweeney, Chester P Gut, Michael L Gargas, et al.
Pageof 4